Ignite Creation Date:
2025-12-24 @ 9:14 PM
Ignite Modification Date:
2025-12-29 @ 4:57 AM
Study NCT ID:
NCT05266404
Status:
COMPLETED
Last Update Posted:
2022-07-05
First Post:
2022-02-23
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase 1 Bioequivalence Study of Dapagliflozin/Sitagliptin FDC vs Loose Combination of Single Components
Sponsor:
AstraZeneca
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-03-21
Start Date Type:
ACTUAL
Primary Completion Date:
2022-05-31
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-05-31
Completion Date Type:
ACTUAL
First Submit Date:
2022-02-23
First Submit QC Date:
None
Study First Post Date:
2022-03-04
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-06-30
Last Update Post Date:
2022-07-05
Last Update Post Date Type:
ACTUAL